0
0
“We’re reaching a juncture where the markets are looking past the Covid-19 pandemic. Vaccine revenue is likely to see little growth or no growth over 2022, per consensus revenue estimates for the likes of Moderna and Pfizer. We think investors will need to evaluate vaccine stocks based on the potential of their future pipelines and other drugs,” noted analysts at TREFIS.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
